Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Jean-Mathieu Beauregard clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Canada register with Jean-Mathieu Beauregard as lead sponsor. Synced 17 Nov 2026
3Current trials
2Recruiting now
1Drug in these trials
1Trial register
At a glance

Jean-Mathieu Beauregard is the lead sponsor of 3 current clinical trials in our Canada register. 2 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Lu-PSMA. The most-studied condition is Metastatic Castrate Resistant Prostate Cancer (mCRPC).

ClinicalTrials.gov trials by status

  • Recruiting267%
  • Not yet open133%

Trials by phase

  • Not applicable267%
  • Phase 1133%
01

Clinical trials sponsored by Jean-Mathieu Beauregard

3 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
NCT06943495 · ClinicalTrials.gov ↗ · Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Drug: Lu-PSMA
Phase 1 Recruiting 2025-08 Canada
Access Study Assessing the Safety of Prostate-specific Membrane Antigen Radioligands for Positron Emission Tomography
NCT07940179 · ClinicalTrials.gov ↗ · Prostate Cancer, Other Cancers
Not applicable Recruiting 2021-11 Canada
Access Study Assessing the Safety of Choline Tracers for Positron Emission Tomography
NCT07940114 · ClinicalTrials.gov ↗ · Hyperparathyroidism
Not applicable Not yet open 2026-12 Canada

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Jean-Mathieu Beauregard trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Jean-Mathieu Beauregard trials

4 conditions
Metastatic Castrate Resistant Prostate Cancer (mCRPC)1Hyperparathyroidism1Prostate Cancer1Other Cancers1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in Canada32

A trial with sites in more than one country appears in each of those registers.

05

Questions about Jean-Mathieu Beauregard trials

How many clinical trials does Jean-Mathieu Beauregard sponsor?

Jean-Mathieu Beauregard is the lead sponsor of 3 current trials on ClinicalTrials.gov in our Canada register, as of the registry sync on 17 November 2026. Completed and withdrawn studies are not counted.

Are Jean-Mathieu Beauregard trials recruiting?

Yes. 2 of its 3 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Jean-Mathieu Beauregard testing?

Its current trials name 1 drug or biological as interventions. The most frequent are Lu-PSMA (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 17 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.